PharmaForm Announces Commercial Manufacturing Contract for Corcept Therapeutics Inc. (CORT)'s Korlym™
3/27/2012 9:06:16 AM
AUSTIN, TX, March 26, 2012 /PRNewswire/ - PharmaForm announced today
that Corcept Therapeutics Inc. has chosen PharmaForm as their primary
commercial manufacturer for their newly approved drug product,
Korlym. The U.S. Food and Drug Administration approved Corcept's
Korlym on February 17th, 2012 for patients with endogenous Cushing's
PharmaForm, a full-service contract provider of development and
manufacturing for the pharmaceutical and biotech industry, has worked
with Corcept for several years as a contract provider for services in
the development, optimization and validation of the manufacturing
process for Corcept's Korlym.
PharmaForm, a wholly-owned subsidiary of Akela Pharma, Inc., is a
leading specialty contract manufacturer for pre-clinical, clinical and
commercial products. PharmaForm specializes in the area of
pharmaceutical dosage form development, controlled release and
bioavailability enhancement technologies, such as hot melt extrusion,
spray drying, fluid bed processing, and liquid filled capsules.
PharmaForm's expertise along with its ability to handle certain class
potent compounds places PharmaForm as a leader in the field of
specialty pharmaceutical dosage formulation and GMP manufacturing.
Through its diverse offerings, PharmaForm's solutions help
pharmaceutical and biotechnology clients reach their drug development
targets, reduce development costs and accelerate time-to-market for
About Akela Pharma, Inc.
Akela Pharma, Inc. is the parent company of PharmaForm, and its common
shares trade on The Toronto Stock Exchange ("TSX") under the symbol
"AKL" with 32.4 million shares outstanding.
This press release contains statements which may constitute
forward-looking information under applicable Canadian securities
legislation or forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1955. Such
forward-looking statements or information may include financial and
other projections as well as statements regarding the company's future
plans, objectives, performance, revenues, growth, profits, operating
expenses or the company's underlying assumptions. The words "may",
"would", "could", "will", "likely", "expect", anticipate", "intend",
"plan", "forecast", "project", "estimate" and "believe" or other
similar words and phrases may identify forward-looking statements or
information. Persons reading this press release are cautioned that such
statements or information are only expectations, and that the company's
actual future results or performance may be materially different.
Forward-looking statements or information in this press release include,
but are not limited to, statements or information concerning our
ongoing drug development programs and collaborations as well as the
possible receipt of future payments upon achievement of milestones.
Such forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments to be materially different from
results, events or developments expressed or implied by such
forward-looking statements or information. Such factors include, among
others, the possibility that risks associated with requirements for
approvals by government agencies such as the FDA before products can be
tested in clinical trials; the possibility that such government agency
approvals will not be obtained in a timely manner or at all or will be
conditioned in a manner that would impair our ability to advance
development; risks associated with the requirement that a drug
candidate be found safe and effective after extensive clinical trials;
our dependence on suppliers, collaborative partners and other third
parties and the prospects and timing for negotiating supply agreements,
corporate collaborations or licensing arrangements; our ability to
attract and retain key personnel; and other factors as described in
detail in our filings with the Canadian securities regulatory
authorities at http:www.sedar.com.
Assumptions underlying our expectations regarding forward-looking
statements or information contained in this press release include,
among others, that future clinical trial results will be favorable;
that our drug candidate will treat target diseases as intended; that we
will raise enough capital, on reasonable terms and in a timely manner;
that we will retain our key personnel; that we will obtain the
necessary regulatory approvals.
In the event that any of these assumptions prove to be incorrect, or in
the event that we are impacted by any of the risks identified above, we
may not be able to continue in our business as planned.
For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings with
Canadian securities regulatory authorities, filed on SEDAR at http://www.sedar.com.
All forward-looking statements and information made herein are based on
our current expectations as of the date hereof and we disclaim any
intention or obligation to revise or update such forward-looking
statements and information to reflect subsequent events or
circumstances, except as required by law.
SOURCE AKELA PHARMA INC.